However, as Smad2 also plays an essential role in the glucose-stimulated release of insulin in β cells 16, targeting Smad3 but not upstream TGFBR1 in islets (β cells) may be more favorable for cell replacement treatment of diabetes. This evidence concerns the gene SMAD3 and diabetes mellitus.